Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="KOGNER, P*" or (type exact bookEditor and editor="KOGNER, P*")

Add to list
- Journal Article
- A1
- open access
Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)

Angela Bellini, Ulrike Pötschger, Virginie Bernard, Eve Lapouble, Sylvain Baulande, Peter F. Ambros, Nathalie Auger, Klaus Beiske, Marie Bernkopf, David R. Betts, et al.

(2021) JOURNAL OF CLINICAL ONCOLOGY. 39(30). p.3377-3390
Add to list
- Journal Article
- A1
- open access
11q deletion or ALK activity curbs DLG2 expression to maintain an undifferentiated state in neuroblastoma

Joachim Tetteh Siaw, Niloufar Javanmardi, Jimmy Van den Eynden (UGent) , Dan Emil Lind, Susanne Fransson, Angela Martinez-Monleon, Anna Djos, Rose-Marie Sjöberg, Malin Östensson, Helena Carén, et al.

(2020) CELL REPORTS. 32(12).
Add to list
Risk stratification of high-risk metastatic neuroblastoma : a report from the HR-NBL-1/SIOPEN study

Daniel A Morgenstern, Ulrike Pötschger, Lucas Moreno, Vassilios Papadakis, Cormac Owens, Shifra Ash, Claudia Pasqualini, Roberto Luksch, Alberto Garaventa, Adela Canete, et al.

(2018) PEDIATRIC BLOOD & CANCER. 65(11).
Add to list
- Journal Article
- A2
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib

Jikui Guan, Susanne Fransson, Joachim Tetteh Siaw, Diana Treis, Jimmy Van den Eynden (UGent) , Damini Chand, Ganesh Umapathy, Kristina Ruuth, Petter Svenberg, Sandra Wessman, et al.

(2018) COLD SPRING HARBOR MOLECULAR CASE STUDIES. 4(4).
Add to list
Accelerating drug development for neuroblastoma - New drug development strategy : an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project

Lucas Moreno, Hubert Caron, Birgit Geoerger, Angelika Eggert, Gudrun Schleiermacher, Penelope Brock, Dominique Valteau-Couanet, Louis Chesler, Johannes Schulte, Katleen De Preter (UGent) , et al.

(2017) EXPERT OPINION ON DRUG DISCOVERY. 12(8). p.801-811
Add to list
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN) : an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D. J. Pearson, Penelope Brock, Roberto Luksch, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Genevieve Laureys (UGent) , Josef Malis, et al.

(2017) LANCET ONCOLOGY. 18(4). p.500-514
Add to list
Emergence of new ALK mutations at relapse of neuroblastoma

Gudrun Schleiermacher, Niloufar Javanmardi, Virginie Bernard, Quentin Leroy, Julie Cappo, Thomas Rio Frio, Gaëlle Pierron, Eve Lapouble, Valérie Combaret, Franki Speleman (UGent) , et al.

(2014) JOURNAL OF CLINICAL ONCOLOGY. 32(25). p.2727-2734
Add to list
- Journal Article
- A1
- open access
ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours

Annica Wilzen, Cecilia Krona, Baldur Sveinbjornsson, Erik Kristiansson, Daniel Dalevi, Ingrid Ora, Katleen De Preter (UGent) , Raymond L Stallings, John Maris, Rogier Versteeg, et al.

(2013) MOLECULAR CANCER. 12.
Add to list
- Journal Article
- A1
- open access
A 6-gene signature identifies four molecular subgroups of neuroblastoma

Frida Abel, Daniel Dalevi, Maria Nethander, Rebecka Jörnsten, Katleen De Preter (UGent) , Joëlle Vermeulen (UGent) , Raymond Stallings, Per Kogner, John Maris and Staffan Nilsson

(2011) CANCER CELL INTERNATIONAL. 11.
Add to list
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification

Sara De Brouwer (UGent) , Katleen De Preter (UGent) , Candy Kumps (UGent) , Piotr Zabrocki, Michael Porcu, Ellen M Westerhout, Arjan Lakeman, Jo Vandesompele (UGent) , Jasmien Hoebeeck (UGent) , Tom Van Maerken (UGent) , et al.

(2010) CLINICAL CANCER RESEARCH. 16(17). p.4353-4362
Add to list
Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the european HR-NBL1/SIOPEN study

Ruth Ladenstein, Domonique Valteau-Couanet, Penelope Brock, Isaac Yaniv, Victoria Castel, Genevieve Laureys (UGent) , Josef Malis, Vassilios Papadakis, Ana Lacerda, Ellen Ruud, et al.

(2010) JOURNAL OF CLINICAL ONCOLOGY. 28(21). p.3516-3524
Add to list
- Journal Article
- A1
Analysis of neuroblastoma tumour progression; loss of PHOX2B on 4p13 and 17q gain are early events in neuroblastoma tumourigenesis

C KRONA, H CAREN, RM SJOBERG, B SANDSTEDT, Genevieve Laureys (UGent) , P KOGNER and T MARTINSSON

(2008) INTERNATIONAL JOURNAL OF ONCOLOGY. 32(3). p.575-583
Add to list
- Journal Article
- A1
Quality assessment of genetic markers used for therapy stratification

IM AMBROS, J BENARD, M BOAVIDA, N BOWN, H CARON, V COMBARET, J COUTURIER, C DARNFORS, O DELATTRE, J FREEMAN-EDWARD, et al.

(2003) JOURNAL OF CLINICAL ONCOLOGY. 21(11). p.2077-2084

Academic Bibliography

Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)

11q deletion or ALK activity curbs DLG2 expression to maintain an undifferentiated state in neuroblastoma

Risk stratification of high-risk metastatic neuroblastoma : a report from the HR-NBL-1/SIOPEN study

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib

Accelerating drug development for neuroblastoma - New drug development strategy : an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN) : an international, randomised, multi-arm, open-label, phase 3 trial

Emergence of new ALK mutations at relapse of neuroblastoma

ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours

A 6-gene signature identifies four molecular subgroups of neuroblastoma

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification

Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the european HR-NBL1/SIOPEN study

Analysis of neuroblastoma tumour progression; loss of PHOX2B on 4p13 and 17q gain are early events in neuroblastoma tumourigenesis

Quality assessment of genetic markers used for therapy stratification

Contents

Support

Contact